Paulli M, Artusi T, Baroni C D, Carbone A, Coggi G, Di Lollo S, Facchetti F, Falini B, Franco V, Gambacorta M, La Rocca V M, Leoncini L, Magrini U, Maiorana A, Menestrina F, Novero D, Palestro G, Pescarmona E, Santucci M, Stracca Pansa V, Truini M, Pileri S
Sezione di Anatomia Patologica, Dipartimento di Patologia Umana ed Ereditaria, I.R.C.C.S. Policlinico S. Matteo, Universita di Pavia.
Pathologica. 2006 Feb;98(1):37-40.
Recently, many progresses have been recorded in the molecular and histogenetic characterization of the haematopoietic and lymphoid tumours, resulting in important classifying changes. As a consequence, the exact definition of lymphoma subtype requires an integration between traditional morphologic "expertise" and several bio-functional data obtained from advanced and complex ancillary techniques (immunohistochemistry, molecular biology and cytogenetics). At the same time, the data provided by gene expression profiling studies are going to deeply modify the therapies in haematological cancers. These studies are expected to allow the achievement of single-patient-tailored genic therapy; for this reason it is necessary to get biological samples of good quality. Indeed, while these progresses contribute to highlight the pathologist's diagnostic role, they should make us reflect on the state of the art of the Italian haemolymphopathology diagnostics and on its ability to cope up with the new challanges. The aim of this article is to outline a realistic picture of the present condition, and to explain the reasons for setting up, inside SIAPEC-IAP, the Haemolymphopathology Italian Group (H.I.G.). The purpose of H.I.G. will be twofold: first of all, scheduling of a series of projects so as to the haemolymphopathological diagnostic standardization; secondly, building a national network among all the pathologists involved in this exciting and complex field of the anatomic pathology.
最近,造血与淋巴组织肿瘤的分子及组织发生学特征研究取得了许多进展,带来了重要的分类变化。因此,淋巴瘤亚型的确切定义需要将传统形态学“专业知识”与从先进复杂的辅助技术(免疫组织化学、分子生物学和细胞遗传学)获得的多种生物功能数据相结合。同时,基因表达谱研究提供的数据将深刻改变血液系统癌症的治疗方法。这些研究有望实现针对单患者的基因治疗;因此,获取高质量的生物样本很有必要。实际上,虽然这些进展有助于凸显病理学家的诊断作用,但它们也应促使我们反思意大利血液淋巴病理学诊断的现状及其应对新挑战的能力。本文旨在勾勒当前状况的现实图景,并解释在意大利血液学与肿瘤病理学会(SIAPEC - IAP)内部成立意大利血液淋巴病理学小组(H.I.G.)的原因。H.I.G.的目的有两个:首先,安排一系列项目以实现血液淋巴病理学诊断的标准化;其次,在所有参与这一解剖病理学中令人兴奋且复杂领域的病理学家之间建立一个全国性网络。